Your fact-checks will appear here
Highest regulatory authority on medicines in the European Union
Reported tallies of "deaths from COVID vaccine" vary widely because they mix raw, unverified reports with adjudicated findings; passive surveillance systems like VAERS show tens of thousands of report...
The 2025–2026 Northern Hemisphere flu vaccines are trivalent and chosen to target one H1N1 A strain, one H3N2 A strain, and one B/Victoria-lineage strain; U.S. regulators (FDA/CDC) recommended these c...
There is no record in the provided sources of any FDA or EMA approval for a “Musk‑linked dementia therapy” as a drug treatment; Musk’s venture Neuralink has regulatory clearance only for human trials ...
Humans acquire parasitic infections through several well-documented routes: ingestion (contaminated food or water), penetration of skin, and via animal or insect vectors such as mosquitoes and ticks —...
Available reporting does not show that a product called "Lipoless" has been approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA); a Paraguayan news article as...
Regulatory agencies and multiple studies since 2021 have linked a very small number of neurological and immune-mediated conditions to the Janssen/Johnson & Johnson (J&J) adenoviral‑vector COVID‑19 vac...
Neuralink — Elon Musk’s neurotechnology company — received U.S. FDA clearance to begin a first‑in‑human clinical study of its brain‑implant device in May 2023, not a full drug approval . Available sou...
Three distinct RSV vaccines authorized in recent years use different active ingredients: protein-based “prefusion F” antigens in Pfizer’s ABRYSVO and GSK’s AREXVY, and a nucleoside‑modified mRNA encod...
In 2024–2025 the main new U.S. approval was Kisunla (donanemab-azbt), granted traditional FDA approval July 2, 2024; regulatory decisions in Europe were mixed, with lecanemab (Leqembi) receiving a con...
The UK has shifted its national programme from quadrivalent to trivalent influenza vaccines because WHO and EU/UK advisers judge B/Yamagata absent since March 2020; all vaccines marketed for 2025–26 i...
The 2024–25 U.S. influenza season was dominated by influenza A, with A(H1N1)pdm09 and A(H3N2) circulating at roughly equal levels and the season classified as high severity; interim U.S. testing found...
Ivermectin is an antiparasitic drug approved for a limited set of human indications — chiefly onchocerciasis, strongyloidiasis and other helminth infections — and is available as oral tablets and topi...
Available sources show major health authorities do not recommend ivermectin to prevent or treat COVID‑19 and that research has produced mixed, largely negative or low‑quality signals for its effective...
Available regulatory databases and news summaries searched here show no entry for a formal recall, warning letter, or safety review specifically naming “Laellium” by FDA or EMA; sources instead docume...
Regulatory reviews and surveillance from 2021 onward identified a small number of rare but serious adverse events after the Janssen (Johnson & Johnson) COVID-19 vaccine — chiefly thrombosis with throm...
The World Health Organization’s current stance is that and should be used only within randomized clinical trials because available evidence shows no convincing, clinically meaningful benefit for key o...
Large observational studies and regulatory reviews consistently find that the most commonly reported long-term issues after mRNA COVID-19 vaccination are , with serious long-term events being rare and...
A large and disparate body of clinical research tested ivermectin for COVID‑19 using regimens ranging from single low antiparasitic doses (≈150–200 μg/kg) to multi‑day high‑dose courses (including stu...
A review of the supplied reporting finds no documented regulatory approvals, marketing authorizations, or official safety warnings for any product named “gelatide” in either the United States or the E...
Michael Yeadon remained active into 2024 in disputing mainstream accounts of COVID‑19 vaccine safety and in publicly demanding media apologies, and at least one 2024 outlet reported he had issued a fo...